Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021.
avoiding drug toxicity
invasive fungal disease
optimising antifungal therapy
patient information
risk prevention
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
entrez:
22
12
2021
pubmed:
23
12
2021
medline:
18
3
2022
Statut:
ppublish
Résumé
Patients with invasive fungal disease (IFD) are at significant risk of morbidity and mortality. A productive partnership between patients, their carers/families, and the multidisciplinary team managing the infection and any underlying conditions, is essential. Sharing information and addressing knowledge gaps are required to ensure those at risk of IFD avoid infection, while those with suspected or confirmed infection optimise their therapy and avoid toxicities. This new addition to the Australian and New Zealand consensus guidelines for the management of IFD and antifungal use in the haematology/oncology setting outlines the key information needs of patients and their carers/families. It specifically addresses risk factor reduction, antifungal agents and adherence, and the risks and benefits of complementary and alternative therapies. Knowledge gaps are also identified to help inform the future research agenda.
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
220-233Investigateurs
Monica A Slavin
(MA)
Karin A Thursky
(KA)
Jason A Roberts
(JA)
Leon J Worth
(LJ)
Christina C Chang
(CC)
Sharon C-A Chen
(SC)
C Orla Morrissey
(CO)
Christopher C Blyth
(CC)
Anna Khanina
(A)
Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Vermeir P, Vandijck D, Degroote S, Peleman R, Verhaeghe R, Mortier E et al. Communication in healthcare: a narrative review of the literature and practical recommendations. Int J Clin Pract 2015; 69: 1257-67.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
Chang CC, Ananda-Rajah M, Belcastro A, McMullan B, Reid A, Dempsey K et al. Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Intern Med J 2014; 44: 1389-97.
Memorial Sloan Kettering Cancer Center. Neutropenic diet 2020. Available from URL: www.mskcc.org/experience/patient-support/nutrition-cancer/diet-plans-cancer/neutropenic-diet
Bouakline A, Lacroix C, Roux N, Gangneux JP, Derouin F. Fungal contamination of food in hematology units. J Clin Microbiol 2000; 38: 4272-3.
Pagano L, Busca A, Candoni A, Cattaneo C, Cesaro S, Fanci R et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Rev 2017; 31: 17-29.
Avery RK, Michaels MG. Strategies for safe living following solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33: e13519.
Igreja RP. Infectious diseases associated with caves. Wilderness Environ Med 2011; 22: 115-21.
Stanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One 2013; 8: e75531.
Maschmeyer G. The changing face of febrile neutropenia - from monotherapy to moulds to mucositis. Prevention of mould infections. J Antimicrob Chemother 2009; 63: i27-30.
Benedict K, Mody RK. Epidemiology of histoplasmosis outbreaks, United States, 1938-2013. Emerg Infect Dis 2016; 22: 370-8.
Park BJ, Sigel K, Vaz V, Komatsu K, McRill C, Phelan M et al. An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis 2005; 191: 1981-7.
Emmons CW. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 1955; 62: 227-32.
Pinana JL, Gomez MD, Montoro J, Lorenzo I, Perez A, Gimenez E et al. Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. Transpl Infect Dis 2019; 21: e13158.
Ng HS, Koczwara B, Roder D, Chan RJ, Vitry A. Patterns of health service utilisation among the Australian population with cancer compared with the general population. Aust Health Rev 2020; 44: 470-9.
Kust D, Samija I, Maric-Brozic J, Svetec B, Miletic M, Mamic G et al. Use of alternative and complementary medicine in patients with malignant diseases in high-volume cancer center and future aspects. Acta Clin Croat 2016; 55: 585-92.
Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000; 18: 2505-14.
Wortmann JK, Bremer A, Eich HT, Wortmann HP, Schuster A, Fuhner J et al. Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care. Med Oncol 2016; 33: 78.
Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 1996; 22: 521-4.
Parize P, Angebault C, de Fonbrune FS, Suarez F, Lecuit M, Lortholary O et al. Naturotherapy as a potential source of mould infections in patients with haematological malignancies. J Hosp Infect 2013; 85: 163-4.
Agrawal S, Rao S, Patole S. Probiotic supplementation for preventing invasive fungal infections in preterm neonates: a systematic review and meta-analysis. Mycoses 2015; 58: 642-51.
Ishikawa KH, Mayer MP, Miyazima TY, Matsubara VH, Silva EG, Paula CR et al. A multispecies probiotic reduces oral Candida colonization in denture wearers. J Prosthodont 2015; 24: 194-9.
Yabes JM, White BK, Murray CK, Sanchez CJ, Mende K, Beckius ML et al. In vitro activity of manuka honey and polyhexamethylene biguanide on filamentous fungi and toxicity to human cell lines. Med Mycol 2017; 55: 334-43.
Cernakova L, Light C, Salehi B, Rogel-Castillo C, Victoriano M, Martorell M et al. Novel therapies for biofilm-based Candida spp. infections. Adv Exp Med Biol 2019; 1214: 93-123.
Bona E, Cantamessa S, Pavan M, Novello G, Massa N, Rocchetti A et al. Sensitivity of Candida albicans to essential oils: are they an alternative to antifungal agents? J Appl Microbiol 2016; 121: 1530-45.
Zuzarte M, Goncalves MJ, Cavaleiro C, Canhoto J, Vale-Silva L, Silva MJ et al. Chemical composition and antifungal activity of the essential oils of Lavandula viridis L'Her. J Med Microbiol 2011; 60: 612-18.
Massa N, Cantamessa S, Novello G, Ranzato E, Martinotti S, Pavan M et al. Antifungal activity of essential oils against azole-resistant and azole-susceptible vaginal Candida glabrata strains. Can J Microbiol 2018; 64: 647-63.
Kara I, Yildirim F, Ozgen O, Erganis S, Aydogdu M, Dizbay M et al. Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient. J Mycol Med 2018; 28: 218-21.
Martin IW, Tonner R, Trivedi J, Miller H, Lee R, Liang X et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis 2017; 87: 286-8.
Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr 2017; 35: 361-4.
Bellete B, Raberin H, Berger C, Flori P, Hafid J, Clemenson A et al. Molecular confirmation of an absidiomycosis following treatment with a probiotic supplement in a child with leukemia [Confirmation par des techniques de biologie moléculaire d'une absidiose après traitement probiotique d'appoint chez une enfant présentant une leucémie aiguë]. J Mycol Méd 2006; 16: 72-6.
Chang GY, Lee KH. Sino-cerebral aspergillosis due to chronic herbal medicine use. QJM 2003; 96: 379.
Cheng CL, Song KP, Chee SP, Chan TK. PCR-aided diagnosis of fungal chorioretinitis following ingestion of traditional Chinese medication. Retina 2002; 22: 803-6.
Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol 2008; 26: 2214-15.
Hamadeh R, Ardehali A, Locksley RM, York MK. Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. Chest 1988; 94: 432-3.
Sutton S, Lum BL, Torti FM. Possible risk of invasive pulmonary aspergillosis with marijuana use during chemotherapy for small cell lung cancer. Drug Intell Clin Pharm 1986; 20: 289-91.
Ng TY, Kang ML, Tan BH, Ngan CC. Case report: enteral nutritional supplement as a likely cause of false-positive galactomannan testing. Med Mycol Case Rep 2014; 3: 11-13.
Rachow T, Dornaus S, Sayer HG, Hermann B, Hochhaus A, von Lilienfeld-Toal M. Case report: false positive elevated serum-galactomannan levels after autologous hematopoietic stem cell transplantation caused by oral nutritional supplements. Clin Case Rep 2016; 4: 505-8.
Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 2018; 36: 2647-55.
Ugalde A, Haynes K, White V, Russell L, Livingston PM. “An ambition to make people feel at home” or “the emperor's new clothes”? Professional stakeholder views of wellness centres in cancer care. Eur J Cancer Care (Engl) 2019; 28: e13096.
Williams AM, Bulsara CE, Joske DJ, Petterson AS, Nowak AK, Bennett KS. An oasis in the hospital: the perceived benefits of a cancer support center in a hospital setting offering complementary therapies. J Holist Nurs 2014; 32: 250-60.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018; 24: e1-e38.
Hoenigl M, Raggam RB, Salzer HJ, Valentin T, Valentin A, Zollner-Schwetz I et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39: 510-13.
Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 2008; 14: 189-93.
Belaiche S, Decaudin B, Dharancy S, Noel C, Odou P, Hazzan M. Factors relevant to medication non-adherence in kidney transplant: a systematic review. Int J Clin Pharmacol 2017; 39: 582-93.
Hall AE, Paul C, Bryant J, Lynagh MC, Rowlings P, Enjeti A et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol 2016; 97: 247-62.
Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol 2017; 11: 215-26.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.
Gillespie D, Hood K, Williams AM, Stenson R, Probert C, Hawthorne A. The use of the medication event monitoring system (MEMS) for assessing medication adherence for chronic conditions: use and results from a 12 month trial of patients in remission with ulcerative colitis (UC). Trials 2011; 12: A130.
Kendrick JG, Ma K, Dezorzi P, Hamilton D. Vomiting of oral medications by pediatric patients: survey of medication redosing practices. Can J Hosp Pharm 2012; 65: 196-201.
O'Mara NB. Re-dosing of selected medications after vomiting 2016. Available from URL: http://canadianpharmacistsletter.therapeuticresearch.com
Yun HY, Baek MS, Park IS, Choi BK, Kwon KI. Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol 2006; 62: 1033-9.
Janssen-Cilag Pty Ltd. Sporonox (intraconazole) Australian approved product information. 2014 Dec 24.
Pfizer Australia Pty Ltd. Vfend (voriconazole) Australian approved product information. 2013 Jan 11.
Kuklinski LF, Li S, Karagas MR, Weng WK, Kwong BY. Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation. J Am Acad Dermatol 2017; 77: 706-12.
Merck Sharp and Dohme (Australia) Pty Ltd. Noxafil (posaconazole) Australian approved product information. 2019 Sep 16.
Hoenigl M, Duettmann W, Raggam RB, Huber-Krassnitzer B, Theiler G, Seeber K et al. Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. Int J Antimicrob Agents 2014; 44: 140-4.
Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-95.
Pfizer Australia Pty Ltd. Cresemba (isavuconazole) Australian approved product information. 2019 May 17.
Lewis R, Bruggemann RJM, Padoin C, Maertens J, Marchetti O, Groll AH et al., editors. Triazole Antifungal Therapeutic Drug Monitoring. European Conference on Infections in Leukaemia (ECIL) 6 meeting; 2015; Sophia Antipolis, France.
Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 2018; 73: 3221-30.
Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-26.
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69: 1162-76.
Brooks KM, George JM, Kumar P. Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products. Expert Rev Clin Pharmacol 2017; 10: 59-79.
Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 2013; 39: 773-83.
Benedict K, Molinari NAM, Jackson BR. Public awareness of invasive fungal diseases - United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69: 1343-6.
Lachenmayr SJ, Strobach D, Berking S, Horns H, Berger K, Ostermann H. Improving quality of antifungal use through antifungal stewardship interventions. Infection 2019; 47: 603-10.
Stolbach A, Paziana K, Heverling H, Pham P. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol 2015; 11: 326-41.
Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf 2012; 3: 241-53.
Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. P T 2017; 42: 473-7.
Humphreys S, Deyermond R, Bali I, Stevenson M, Fee JP. The effect of high altitude commercial air travel on oxygen saturation. Anaesthesia 2005; 60: 458-60.
Ahmedzai S, Balfour-Lynn IM, Bewick T, Buchdahl R, Coker RK, Cummin AR et al. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2011; 66: i1-30.
Josephs LK, Coker RK, Thomas M. Managing patients with stable respiratory disease planning air travel: a primary care summary of the British Thoracic Society recommendations. Prim Care Respir J 2013; 22: 234-8.
Boel NM, Klokker M. Upper respiratory infections and barotrauma among commercial pilots. Aerosp Med Hum Perform 2017; 88: 17-22.
Chau MM, Daveson K, Alffenaar J-WC, Gwee A, Ho SA, Marriott DJE et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients. Intern Med J 2021; 51(Suppl. 7): 37-66.